SALT LAKE CITY – October 28, 2026 -- Thorne converted 80% of its paper batch records to electronic batch records (EBR) in 2026 using MasterControl Manufacturing Excellence (Mx), earning the Manufacturing Excellence Award at MasterControl's 2026 Masters Summit. The October event named four winners of the Masters of Excellence Awards, which recognize MasterControl customers in quality management, manufacturing, asset excellence and innovation.
Thorne targets full electronic batch record rollout by year-end
Thorne aims to complete its EBR implementation by the end of 2026, with MasterControl Logbooks planned next. After five years on MasterControl, the company reports measurable gains in right-first-time rates, record review and release times, and quality performance.
Thorne simplified its workflows but kept the multiple inspections, process controls and verification checks in its master manufacturing records. System validation, controlled access, audit trails and electronic signature controls supported compliance with applicable electronic recordkeeping and signature requirements.
Jamieson Wellness standardizes documentation across eight departments
Anthony Contreras, quality system compliance director at Jamieson Wellness, won the Quality Champion award. Using MasterControl, he delivered consistent documentation and streamlined processes across eight departments. MasterControl credits him with improving audit readiness and fostering cross-functional collaboration.
NeoGenomics tests Elemental Machines, Azure Data Factory and Qualer Identity integrations
NeoGenomics received the Asset Excellence recognition, represented by Systems & Implementation Supervisor Faizan Ahmed. The company has increased its investment over time and expanded platform use across the organization. It also tests and validates new features and integrations, including Elemental Machines, Azure Data Factory (ADF) and Qualer Identity, and gives MasterControl feedback on the platform's direction.
Natera's Signatera wins FDA companion diagnostic approval for bladder cancer
Natera received the Innovation Excellence recognition, represented by Kathryn Bell, senior director of quality assurance, and Jacqueline Jaskula, vice president of regulatory affairs. More than 400 peer-reviewed publications support the company's cell-free DNA (cfDNA) technology across women's health, oncology and organ health.
In 2026, its Signatera molecular residual disease (MRD) test received U.S. Food and Drug Administration companion diagnostic approval for muscle-invasive bladder cancer. Signatera also became the first MRD test approved by Japan's Pharmaceuticals and Medical Devices Agency (PMDA). It was incorporated into National Comprehensive Cancer Network (NCCN) guideline recommendations for bladder cancer patients. Natera's portfolio also includes the Panorama noninvasive prenatal test and the Prospera transplant assessment test.
MasterControl CEO David Edwards said the winners demonstrate "the real business impact that connected solutions can deliver," from data-driven quality cultures to advanced manufacturing and diagnostic innovation.